Helping GT entrepreneurs learn how to fund and commercialize their technology.

"A Venn Diagram of Science, Medicine, Finance, and Business Management"

Jack Krieger, Ph.D.
Director, Portfolio Intelligence
BridgeBio

REGISTER HERE - participation link to be provided upon submission

AGENDA
11:00 a.m.                Seminar
Noon-12:30 p.m.      Extended "Office Hours" discussion

ABSTRACT
Bringing biomedical technologies to patients at scale requires not just deep subject matter expertise, but also “hybrid” capabilities that straddle multiple disciplines. In this session I’ll share my reflections from biotech on what “interdisciplinary” means in the pharmaceutical and medical product ecosystem.

BIO
In his role in portfolio intelligence, Jack Krieger develops and delivers recommendations for executive leadership on capital allocation, R&D strategy, and competitive intelligence across the BridgeBio's portfolio of genetic disease medicines. He has business development experience, leading the diligence of an indication expansion opportunity.

Krieger also co-leads with a cross-functional team the scientific strategy and operations of the preclinical program for autism spectrum disorder associated with PTEN gene variants.

The series is hosted by the Parker H. Petit Institute for Bioengineering and Bioscience and GT's VentureLab. For inquiries or suggestions about future seminars, contact Cynthia Sundell, Senior Director of Life Sciences, IBB, or Harold Solomon, Principal, VentureLab.